Novartis Venture Fund — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.
BiotechMedical DevicesBasel, CH
Patrick Loustau(President and Chief Executive Officer)
Co-investorsSanofi VenturesForbionVersant Ventures
Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins.
BiotechDeep TechMedical DevicesBurlington, US
KLEEM CHAUDHARY(Executive Officer, Director, Promoter)Ku-Lung (Ken) Hsu, PhD(Endowed Associate Professor of Chemistry)Kleem Chaudhary, PhD(President & CEO)
BoardJOHN GUSTOFSON(Director)LAURA BRASS(Director)inLAURA TADVALKAR(Director)
Co-investorsDroia VenturesEisai Innovation, Inc.RA Capital
Atalanta develops RNA interference-based therapeutics aimed at treating central nervous system and neurological diseases.
BiotechHealthtech
Co-investorsF-Prime CapitalRiverVest Venture PartnersSanofi Venturesabrdn plcEQT Life Sciences
NRG Therapeutics is a clinical-stage neuroscience drug discovery company developing disease-modifying, oral small-molecule medicines that target mitochondrial function via inhibition of the mitochondrial permeability transition pore.
BiotechHealthtechLongevity
Co-investorsCriteria Bio VenturesM VenturesSV Health InvestorsBritish Business BankDementia Discovery Fund
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.